Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
Rhea-AI Summary
Omada Health (Nasdaq: OMDA) reported preliminary, unaudited revenue for Q4 2025 of $72M–$74M (up ~50%–54% YoY) and full-year 2025 revenue of $256M–$258M (up ~51%–52% YoY). Total members reached approximately 886,000 as of December 31, 2025, a 55% increase year-over-year. Results are preliminary and subject to completion of year-end closing procedures and the annual independent audit. Omada plans to release audited Q4 and FY2025 results on March 5, 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Positive
- Preliminary full-year revenue $256M–$258M (+51%–52% YoY)
- Preliminary Q4 revenue $72M–$74M (+50%–54% YoY)
- Total members ~886,000 as of Dec 31, 2025 (+55% YoY)
- Company expanded GLP-1 care offerings and advanced AI on platform
Negative
- Revenue figures are preliminary and unaudited, subject to adjustment
- Audited results not available until March 5, 2026, creating timing uncertainty for investors
News Market Reaction
On the day this news was published, OMDA gained 4.61%, reflecting a moderate positive market reaction. This price movement added approximately $39M to the company's valuation, bringing the market cap to $892M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OMDA fell 6.27% while key peers were mixed: SDGR and TDOC declined (-2.34%, -3.37%), but GDRX, OMCL, and PHR posted modest gains. This points to a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | GLP-1 outcomes data | Positive | -0.8% | 12‑month real‑world GLP-1 analysis showing strong, durable weight loss. |
| Dec 22 | Conference participation | Neutral | +6.8% | Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 20 | Conference participation | Neutral | -4.9% | Notice of participation and fireside chat at Evercore Healthcare Conference. |
| Nov 06 | Quarterly earnings | Positive | -6.1% | Q3 2025 results with 49% revenue growth and first positive adjusted EBITDA. |
| Nov 06 | GLP-1 capability news | Positive | -6.1% | Nationwide GLP-1 prescribing capability added to weight program offering. |
Positive fundamental and GLP-1-related news has often coincided with flat or negative next-day moves, while conference participation headlines have sometimes drawn more favorable reactions.
Over the last few months, Omada has reported strong growth and expanding GLP-1 capabilities. Q3 2025 results on Nov 06 showed revenue of $68.0M, 53% member growth, improved margins, and first positive adjusted EBITDA, yet the stock fell 6.14%. Subsequent GLP-1 behavior-change data on Jan 08, 2026 also saw a mild decline. In contrast, the announcement of participation in the 44th Annual J.P. Morgan Healthcare Conference on Dec 22 coincided with a 6.83% gain. Today’s preliminary 2025 revenue update continues the theme of rapid top-line and member growth.
Market Pulse Summary
This announcement highlights substantial scale-up in Omada’s business, with preliminary Q4 2025 revenue of $72–$74 million, full-year revenue of $256–$258 million, and members reaching about 886,000, a 55% year-over-year increase. It reinforces earlier disclosures of rapid growth and expanding GLP-1 and AI-enabled offerings. Investors may watch the audited results expected on March 5, 2026, along with any updates to profitability metrics and member engagement trends disclosed in prior filings.
Key Terms
glp-1 medical
ai technical
forward-looking statements regulatory
u.s. private securities litigation reform act of 1995 regulatory
securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be between
Omada also announced that total members reached approximately 886,000 as of December 31, 2025, an increase of
The unaudited results in this press release are preliminary and subject to the completion of Omada’s final closing procedures and annual independent audit and are subject to adjustment.
“Our preliminary 2025 results underscore the growing relevance of our between-visit care model as both buyers and members seek new solutions,” said Sean Duffy, Omada’s Co-founder and CEO. “During the year, we enhanced our GLP-1 care offerings and advanced the use of AI across our platform with an aim to drive sustainable member outcomes and support customers navigating evolving cost and care dynamics.”
Omada expects to report its audited fourth quarter and fiscal year 2025 results on March 5, 2026, after the close of market. Details for the conference call and webcast will be announced at a later date.
About Omada Health
Omada Health (Nasdaq: OMDA) is on a mission to fix what’s broken in chronic care. Today's healthcare system poorly serves chronic conditions that require ongoing support between doctor visits, like obesity, diabetes, hypertension, and musculoskeletal disorders. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than one million members since launch across 2,000+ employers, health plans, and health systems. Learn more at omadahealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding future financial and operating results, and our financial outlook.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to achieve or maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.
Investor Relations Contact
Allan Kells
ir@omadahealth.com
Media Contact:
Rose Ramseth
press@omadahealth.com
FAQ
What preliminary Q4 2025 revenue did Omada Health (OMDA) report?
What is Omada Health's preliminary full-year 2025 revenue (OMDA)?
How many members did Omada (OMDA) report at year-end 2025 and what is the growth rate?
When will Omada (OMDA) release audited Q4 and FY2025 financial results?
Does Omada's announcement affect its conference schedule at J.P. Morgan?
